skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Viral vectors for cystic fibrosis gene therapy: What does the future hold?

Review

(2370) Views  (1154) Full article downloads

Authors: Uta Griesenbach, Makoto Inoue, Mamoru Hasegawa, et al

Published Date December 2010 Volume 2010:2 Pages 159 - 171
DOI: http://dx.doi.org/10.2147/VAAT.S8887

Uta Griesenbach1, Makoto Inoue2, Mamoru Hasegawa2, Eric WFW Alton1
1Department of Gene Therapy, Imperial College London, UK; The UK Cystic Fibrosis Gene Therapy Consortium; 2DNAVEC Corporation, Tsukuba, Japan

Abstract: Gene transfer to the airway epithelium has been more difficult than originally anticipated, largely because of significant extra- and intracellular barriers in the lung. In general, viral vectors are more adapted to overcoming these barriers than nonviral gene transfer agents and are, therefore, more efficient in transferring genes into recipient cells. Viral vectors derived from adenovirus, adeno-associated virus, and Sendai virus, which all have a natural tropism for the airway epithelium, have been evaluated for cystic fibrosis (CF) gene therapy. Although these vectors transduce airway epithelial cells efficiently, gene expression is transient and repeated administration is inefficient. They are, therefore, unlikely to be suitable for CF gene therapy. More recently, lentiviruses (LV) have been assessed for lung gene transfer. In contrast to retroviruses, they transduce nondividing cells and randomly integrate into the genome. However, LVs do not have a natural tropism for the lung, and a significant amount of effort has been put into pseudotyping these vectors with proteins suitable for airway gene transfer. Several studies have shown that LV-mediated transduction leads to persistent gene expression (for the lifetime of the animal) in the airways and, importantly, repeated administration is feasible. Thus, appropriately pseudotyped LV vectors are promising candidates for CF gene therapy. Here, we will review preclinical and clinical research related to viral CF gene therapy.

Keywords: cystic fibrosis, gene therapy, adenovirus, AAV, lentivirus, Sendai virus






Readers of this article also read:

Is gene activity in plant cells affected by UMTS-irradiation? A whole genome approach
Methods, potentials, and limitations of gene delivery to regenerate central nervous system cells
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Functional mobility and balance in community-dwelling elderly submitted to multisensory versus strength exercises
The Moses Mabhida Medical Plan: medical care planning and execution at a FIFA2010 stadium; the Durban experience
Erratum - Intracellular heavy metal nanoparticle storage
Targeting nicotine addiction: the possibility of a therapeutic vaccine
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy
Erratum
Mapping protein–RNA interactions
  • Testimonials

    "You do a tremendous job!!" Ruben Restrepo, The University of Texas Health Science Center at San Antonio